<DOC>
	<DOCNO>NCT00504439</DOCNO>
	<brief_summary>To assess safety SB-656933 follow repeat dose 14 day .</brief_summary>
	<brief_title>A Study To Evaluate The Safety And Tolerability Of SB-656933-AAA Following Repeated Doses In Healthy Adult Subjects .</brief_title>
	<detailed_description>A randomised , double-blind , placebo control , dose ascending , parallel group study evaluate safety , tolerability , steady state pharmacokinetics pharmacodynamics SB-656933-AAA follow repeat dos healthy adult subject . The pharmacokinetic interaction repeat dose SB-656933-AAA single dose simvastatin also assess .</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<criteria>Healthy adult female , age 1865 year . Female must able child . Nonsmoking last 6 month . Any serious medical condition . Hepatitis B C and/or HIV positive . Currently HRT , medication except paracetamol . Body Mass Index &gt; 30 .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>SB-656933 ,</keyword>
	<keyword>COPD ,</keyword>
	<keyword>CXCR2 ,</keyword>
	<keyword>CD11b ,</keyword>
	<keyword>repeat dose ,</keyword>
	<keyword>safety ,</keyword>
	<keyword>tolerability .</keyword>
</DOC>